Thursday, 16 February 2017

Compound in cannabis does not look Dope

van Amerongen et al. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. Clin Ther. 2017 Feb 9. pii: S0149-2918(17)30054-1

PURPOSE: The aim of the present study was to evaluate the efficacy of an oral formulation of Δ9-tetrahydrocannabinol (ECP002A) in patients with progressive multiple sclerosis (MS).


METHODS: This accelerated proof-of-concept study consisted of 2 phases: a crossover challenge (dose-finding) phase and a 4-week, parallel, randomized, placebo-controlled treatment phase. Twenty-four patients with progressive MS and moderate spasticity were enrolled. During the treatment phase, biomarkers for efficacy and secondary pharmacodynamic effects were measured at baseline and after 2 and 4 weeks of treatment. Serum samples were collected to determine pharmacokinetic properties and perform population modeling. Safety and tolerability profiles were assessed based on adverse events and safety measurements.


FINDINGS: Pain was significantly reduced when measured directly after administration of ECP002A in the clinic but not when measured in a daily diary. A similar pattern was observed in subjective muscle spasticity. Other clinical outcomes were not significantly different between active treatment and placebo. Cognitive testing indicated that there was no decline in cognition after 2 or 4 weeks of treatment attributable to ECP002A compared with placebo. Implications This study specifically underlines the added value of thorough investigation of pharmacokinetic and pharmacodynamic associations in the target population. Despite the complex interplay of psychoactive effects and analgesia, the current oral formulation of Δ9-tetrahydrocannabinol may play a role in the treatment of spasticity and pain associated with MS because it was well tolerated and had a stable pharmacokinetic profile.


This study looks at oral THC in spasticity and pain and the simple answer is it failed?

Why because the outcomes will have been self-assessed; the sativex study says that it did not work on the scientific outcomes, but on how people were feeling. 

In this study people were obviously not feeling good enough.

They say it is of value..... because it is well tolerated, so is a glass of water, but is that going to treat your pain and spasticity? 

The only thing it worked on was when the people were in clinic.

Was the study big enough to be of value, I suspect not.

CoI: I'm a competitor

3 comments:

  1. I find that when I take the oils from mariguana or if I smoke it on the weekends normally my body feels way more relaxed so I guess it works but on short a term effect

    ReplyDelete
    Replies
    1. In studies above they try to get an effect without the high..but as the the things causing the high are the things causing the therapeutic effect are the same you don't get one without the other.

      Smoke cannabis and you will get a high, then it is easy to show effects as trials have already shown. You post confirms this.

      Delete
  2. MD, is the reference to Sativex meant to infer that the method of consumption of that drug being an oral spray may equate with this oral THC trial drug? My understanding of Sativex is that it includes other cannibinoids as well. Sativex will be able to be legally prescribed to MSers in my Stste on 1 March. It will be interesting to see what the uptake will be by MSers. (Not me).

    Anecdotally, the MSers that I know who smoke the weed would agree with anonymous above.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.